But there are no efficacy data, and the mechanism has a mountain to climb.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
The company will acquire ImCheck for €350m.
